|
Apr 5
|
NGM Bio Announces Closing of Tender Offer
|
|
Mar 19
|
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
|
|
Mar 11
|
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates
|
|
Mar 11
|
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
|
|
Mar 7
|
Why NGM Biopharmaceuticals (NGM) Might Surprise This Earnings Season
|
|
Feb 20
|
NGM Bio to Participate in the Cowen 44th Annual Health Care Conference
|
|
Jan 9
|
NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need
|
|
Jan 3
|
Great week for NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) institutional investors after losing 75% over the previous year
|
|
Nov 7
|
NGM Bio to Participate in Upcoming Investor Conferences
|
|
Nov 2
|
NGM Biopharmaceuticals Inc (NGM) Reports Q3 2023 Financial Results
|
|
Nov 2
|
NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Misses Revenue Estimates
|
|
Nov 2
|
NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights
|
|
Aug 9
|
Time To Worry? Analysts Just Downgraded Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Outlook
|
|
May 1
|
Analysts Estimate ADC Therapeutics SA (ADCT) to Report a Decline in Earnings: What to Look Out for
|
|
Apr 27
|
NGM Biopharmaceuticals (NGM) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
|